Scientific exchange · Dr. Emiko Quinn

03 May 2026 · Virtual · Dr. Emiko Quinn, Kyoto University Hospital · MSL James Whitfield · Vantrexa

ReviewedVeeva CRMENG-0009MI request

Capture insight from this engagement

Location: Kyoto University Hospital
Therapeutic area: Oncology
Country: Japan
Stakeholder tier: Tier 3
Strategic objective: Not linked
Initiative: Not linked
MSL: JWJames WhitfieldSenior MSL, Oncology (US East)
Product: Vantrexa (vantrelimab)

Topics discussed

Sequencing after progression
Elderly / ECOG 2 patients
Chemotherapy-free first line

Scientific content used

VOYAGE-1 pivotal data summary

Questions raised

What was the median PD-L1 testing turnaround in the pivotal trial sites?

Notes

Scientific exchange with radiation oncologist at Kyoto University Hospital. Discussed sequencing after progression, elderly / ecog 2 patients, chemotherapy-free first line.

Insights captured (0)

Capture insight

No insights captured from this engagement.

Review workflow

Draft
Submitted
3Reviewed

Review complete. Quality ratings and insights can now be used in aggregates.

Follow-ups

Send publication reprint

0 of 1 complete

Quality ratings

1–5, rated at review

Scientific relevance: 2
Strategic relevance: 2
Depth of exchange: 1
Actionability: 3

Data lineage

Source system: Veeva CRM
Sync: Veeva CRM · synced 2026-09-15 08:00 UTC
System of record: Veeva CRM
Record id: ENG-0009

Audit history (0)

All create, update and approval events for this record

No audit events in sample data